Research and Markets: Pathway Analyzer for the Rational Application and Combinations of Protein Kinase Inhibitor Drugs in Oncology - 2013: From Bench to Bedside

Business Wire

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/twwslj/pathway_analyzer) has announced the addition of the "Pathway Analyzer for the Rational Application and Combinations of Protein Kinase Inhibitor Drugs in Oncology: From Bench to Bedside" report to their offering.

Protein kinases are key regulators of cell function that constitute one of the largest and most functionally diverse gene families with approximately 518 kinases encoded by the human genome. They direct the activity, localization and overall function of many proteins, and serve to orchestrate the activity of almost all cellular pathways. Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiological constraints on growth and survival.

To date, the industry is developing cancer drugs targeting close to 30% of all known human protein kinases and 29 kinase inhibitors have so far received approval as cancer treatments. As kinase signaling cascades involve an intricate array of interconnected circuits we need to develop more sophisticated modeling of how they are reprogrammed in response to oncogenic events and in the presence of inhibitors. This information will be vital to more rational application and combinations of different inhibitors dependent on the molecular profile of the tumor.

The report "Pathway Analyzer for the Rational Application and Combinations of Protein Kinase Inhibitor Drugs in Oncology: From Bench to Bedside" is a novel tool for instant, interactive pathway modeling on close to 725 protein kinase inhibitor drugs across more than 125 different kinase targets or 95 different tumor types. It serves the purpose of giving you a breakdown analysis of how successful the industry is today in targeting various signaling pathways with kinase inhibitors in oncology or to research new treatment options with the same. You dynamically control the pathway modeling with up to 24 different parameter settings, including both traditional drug development data such as status, indication etc. as well as system biology information such as mutation profile, protein expression, pathway etc. Moreover, each parameter supports multi-select options and can be used as either an inclusion or exclusion parameter for your modeling. Furthermore, your modeling and analysis results are presented to you in a report supported by graphical visualization aids such as charts, diagrams and tables. As an additional value this tool also gives you instant access to extensive drug developmental profiles of all 724 protein kinase inhibitor drugs included.

All together this tool gives you superiority in access and control over drug development options when it comes to protein kinase inhibitors in oncology, not commercially available anywhere else.

For more information visit http://www.researchandmarkets.com/research/twwslj/pathway_analyzer

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contact:
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Rates

View Comments (0)